▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / PMCB

PMCB — PharmaCyte Biotech, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1157075 ·
Last close
$0.79
Market Cap
$8.43M
52W High
$0.97
52W Low
$0.63
ADV30
251,620
Next earnings
—
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jan 2026 0 — -2,118,102 746,860 55,873,565 20,165,535 16,471,229
Oct 2025 0 — -1,376,051 -7,417,975 55,976,469 15,406,017 19,422,384
Jul 2025 0 — -848,305 -8,360,096 45,110,453 13,178,305 1,518,865
Apr 2025 0 — -1,041,864 11,749,582 55,168,353 15,172,163 3,277,284

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,800,723
Investing CF
$2,000,000
Financing CF
$6,579,852
CapEx
—
Dividends Paid
—
Buybacks
$-735,774
EPS Diluted TTM
$-3.08
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-100,000,171
Inventory
—
Receivables
$0
ST Investments
$372,251
EBIT TTM
$-5,384,322
Pretax Income TTM
$-3,281,629
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Apr 2025 0 -4,377,862 30,656,050 55,168,353 3,277,284 — -2,978,296
Apr 2024 0 -6,520,008 333,763 59,903,883 20,389,264 — -2,151,457
Apr 2023 0 -6,455,494 -4,315,993 73,276,925 586,581 — -3,793,731

TTM Snapshot

Revenues TTM
$6,626
NetIncome TTM
$-510,517
OpCashFlow TTM
$0
Assets (Latest)
$2,876,931
Forward EPS
$-0.38

Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.79 · call volume: 3 · put volume: 10

Peers — same industry

TickerNameMarket CapLastDaily %
CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. $8.65M $2.34 —
LIMN Liminatus Pharma, Inc. $7.36M $0.16 —
BCLI BRAINSTORM CELL THERAPEUTICS INC. $6.95M $0.63 —
BCDA BioCardia, Inc. $10.36M $0.91 —
BCAB BioAtla, Inc. $6.48M $3.91 —

News headlines (Yahoo Finance, 1h cache)

BC-Most Active Stocks
2025-12-04 15:30 · Yahoo
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
2025-11-25 14:15 · Yahoo
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
2025-08-20 13:15 · Yahoo
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
2025-08-18 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →